[Antidepressants with different action mechanisms in the treatment of chronic daily headache].
Efficacy and safety of the following antidepressants: amitryptiline (tricyclic antidepressant), escitalopram (selective inhibitor of serotonin reuptake), milnacipran (selective inhibitor of serotonin and noradrenalin reuptake) and maprotiline (selective inhibitor of noradrenalin reuptake) have been compared during the treatment of 120 patients with chronic daily headache. A positive effect was found for all drugs, in particular in the presence of depressive and anxiety symptoms. Most effective proved to be milnacipran and amitryptiline. Escitalopram and milnacipran were more tolerable and had less side-effects. The authors suggested that the combination of noradrenergic and serotoninergic components appears to be most effective in treatment of chronic daily headache.
Amelin
A V
AV
Tarasova
S V
SV
Ignatov
Iu D
IuD
Skoromets
A A
AA
Miatleva
M I
MI
D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000639:Amitriptyline / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use*; D015283:Citalopram / Q000627:therapeutic use; D003521:Cyclopropanes / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005260:Female; D005500:Follow-Up Studies; D006261:Headache / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008376:Maprotiline / Q000627:therapeutic use; D008875:Middle Aged; D000078764:Milnacipran; D010147:Pain Measurement; D012189:Retrospective Studies; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D012720:Severity of Illness Index; D016896:Treatment Outcome
D018759:Adrenergic Uptake Inhibitors; D000639:Amitriptyline; D000928:Antidepressive Agents; D015283:Citalopram; D003521:Cyclopropanes; D008376:Maprotiline; D000078764:Milnacipran; D017367:Selective Serotonin Reuptake Inhibitors